# Mark Foster

> Mark Foster is the president and CEO of CurvaFix, a Bellevue, Washington medical device company building curved intramedullary implants that follow the natural bend of the pelvis to repair fractures. He took the top job in July 2023, the same week the company closed a $39 million Series C led by MVM Partners, and his mandate is commercial scale: turning a novel, FDA-cleared implant into a nationally distributed product. Before CurvaFix he ran Trice Medical and led the U.S. sports medicine business at Smith & Nephew, part of roughly 24 years spent almost entirely inside orthopedics and medical devices.

- **Role:** President and CEO at CurvaFix, Inc.
- **Organizations:** CurvaFix, Inc., Trice Medical, Smith & Nephew, Boston Scientific, Covidien, GlaxoSmithKline
- **Nationality:** American
- **Education:** Bachelor of Arts, University of Richmond
- **Known for:** Appointed president and CEO of CurvaFix in July 2023, succeeding the founder, Led CurvaFix through a $39 million Series C financing round backed by MVM Partners and Sectoral Asset Management, Oversaw FDA 510(k) clearance of the CurvaFix Low Profile System in September 2025

## Career timeline

- **1990s-2000s** — Senior management roles at GlaxoSmithKline Poland and Covidien
- **2000s** — Spent roughly seven years at Boston Scientific, including director of sales operations and training in the neurovascular division
- **2008-2016** — About eight years at Smith & Nephew, rising to Vice President of the U.S. Sports Medicine business
- **2016** — Joined Trice Medical as chief commercialization officer
- **2018** — Added the title of president at Trice Medical
- **2019** — Promoted to CEO of Trice Medical
- **2023** — Named president and CEO of CurvaFix in July, succeeding founder Steve Dimmer, as the company closed a $39M Series C
- **2025** — Oversaw FDA 510(k) clearance of the CurvaFix Low Profile System (Sept) and a Premier Inc. Technology Breakthrough Designation (Nov)

## Achievements

- Appointed president and CEO of CurvaFix in July 2023, succeeding the founder
- Led CurvaFix through a $39 million Series C financing round backed by MVM Partners and Sectoral Asset Management
- Oversaw FDA 510(k) clearance of the CurvaFix Low Profile System in September 2025
- Secured a Premier Inc. Technology Breakthrough Designation for general orthopedic trauma products in November 2025, opening national GPO market access
- Previously rose from chief commercialization officer to CEO at Trice Medical (2016-2019 onward)
- Led the U.S. Sports Medicine business as VP at Smith & Nephew

## Latest updates

- **2025-11** — CurvaFix awarded a Technology Breakthrough Designation for general orthopedic trauma products by Premier Inc., expanding national GPO market access.
- **2025-09** — FDA grants 510(k) clearance to the CurvaFix Low Profile System, featuring a 65% smaller head and implants up to 210mm long.
- **2023-07** — Foster named president and CEO of CurvaFix as the company closes a $39M Series C led by MVM Partners.

## Links

- Website: https://curvafix.com
- LinkedIn: https://www.linkedin.com/in/mark-foster-meddevice/

---

Profile page: https://yespress.io/mark-foster
Published by YesPress — https://yespress.io
Last updated: 2026-07-09